Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
about
The regulatory role of DPP4 in atherosclerotic disease.Tackling dipeptidyl peptidase IV in neurological disorders.Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats.Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis
P2860
Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dipeptidyl peptidase-4 inhibit ...... LP-1 in non-diabetic subjects.
@en
Dipeptidyl peptidase-4 inhibit ...... LP-1 in non-diabetic subjects.
@nl
type
label
Dipeptidyl peptidase-4 inhibit ...... LP-1 in non-diabetic subjects.
@en
Dipeptidyl peptidase-4 inhibit ...... LP-1 in non-diabetic subjects.
@nl
prefLabel
Dipeptidyl peptidase-4 inhibit ...... LP-1 in non-diabetic subjects.
@en
Dipeptidyl peptidase-4 inhibit ...... LP-1 in non-diabetic subjects.
@nl
P2093
P2860
P1433
P1476
Dipeptidyl peptidase-4 inhibit ...... LP-1 in non-diabetic subjects.
@en
P2093
Atsuko Abiko
Hidemitsu Sakagami
Hiroya Kitsunai
Masakazu Haneda
Tsuyoshi Yanagimachi
Yasutaka Takeda
Yuichi Makino
Yukihiro Fujita
Yumi Takiyama
P2860
P304
P356
10.1016/J.MOLMET.2016.12.009
P577
2016-12-31T00:00:00Z